may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and imipramine both increase sedation. Use Caution/Monitor.dexfenfluramineimipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.dexmedetomidinedexmedetomidine and imipramine both increase sedation. Use Caution/Monitor.dexmethylphenidateimipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineimipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.imipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.dextroamphetamine transdermalimipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.dextromoramidedextromoramide and imipramine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and imipramine both increase sedation. Use Caution/Monitor.diazepamdiazepam and imipramine both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, imipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dicyclominedicyclomine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diethylpropionimipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and imipramine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and imipramine both increase sedation. Use Caution/Monitor.dihydroergotamineimipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalimipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.diltiazemdiltiazem will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinatedimenhydrinate and imipramine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and imipramine both increase sedation. Use Caution/Monitor.diphenoxylate hcldiphenoxylate hcl and imipramine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and imipramine both increase sedation. Use Caution/Monitor.dobutamineimipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dolasetronimipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil and imipramine both increase QTc interval. Use Caution/Monitor.dopamineimipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexamineimipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.doxepindoxepin and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepin and imipramine both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and imipramine both increase sedation. Use Caution/Monitor.droperidoldroperidol and imipramine both increase sedation. Use Caution/Monitor.duloxetineduloxetine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.echothiophate iodideechothiophate iodide increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzefavirenz will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.efavirenz and imipramine both increase QTc interval. Use Caution/Monitor.elagolixelagolix will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.eletriptaneletriptan and imipramine both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat increases levels of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eliglustat and imipramine both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.entrectinibentrectinib and imipramine both increase QTc interval. Use Caution/Monitor.ephedrineimipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.epinephrineimipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.epinephrine inhaledimipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.epinephrine racemicimipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.ergotamineimipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulineribulin and imipramine both increase QTc interval. Use Caution/Monitor.erythromycin baseerythromycin base will increase the level or effect of imipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of imipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of imipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.erythromycin stearateerythromycin stearate will increase the level or effect of imipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.esketamine intranasalesketamine intranasal, imipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateeslicarbazepine acetate will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.esomeprazoleesomeprazole will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.estazolamestazolam and imipramine both increase sedation. Use Caution/Monitor.ethanolimipramine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and imipramine both increase sedation. Use Caution/Monitor.etravirineetravirine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fedratinib will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.felbamatefelbamate will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.felodipinefelodipine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fenfluramineimipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, imipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fesoterodinefesoterodine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazolefexinidazole will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fingolimodfingolimod and imipramine both increase QTc interval. Use Caution/Monitor.flavoxateflavoxate and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainideimipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluconazolefluconazole will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fluoxetineimipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and imipramine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and imipramine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.formoterolimipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fosamprenavirfosamprenavir will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosaprepitantfosaprepitant will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetimipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosphenytoinfosphenytoin will decrease the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.frovatriptanfrovatriptan and imipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentingabapentin, imipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, imipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantaminegalantamine increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.ganaxoloneimipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and imipramine both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and imipramine both increase QTc interval. Use Caution/Monitor.glycopyrrolateglycopyrrolate and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.imipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.imipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.glycopyrronium tosylate topicalglycopyrronium tosylate topical, imipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetrongranisetron and imipramine both increase QTc interval. Use Caution/Monitor.grapefruitgrapefruit will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.haloperidolhaloperidol and imipramine both increase sedation. Use Caution/Monitor.henbanehenbane and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodonehydrocodone, imipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphonehydromorphone and imipramine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and imipramine both increase sedation. Use Caution/Monitor.hydroxyzine and imipramine both increase QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneimipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and imipramine both increase sedation. Use Caution/Monitor.imatinibimatinib will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.indacaterol, inhaledindacaterol, inhaled, imipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.indinavirindinavir will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ipratropiumipratropium and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isofluraneisoflurane and imipramine both increase QTc interval. Use Caution/Monitor.isoniazidisoniazid will increase the level or effect of imipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.isoniazid will increase the level or effect of imipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.imipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenolimipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketamineketamine and imipramine both increase sedation. Use Caution/Monitor.ketoconazoleketoconazole will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketotifen, ophthalmicimipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophanimipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibimipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, imipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.imipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lemborexantlemborexant, imipramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.letermovirletermovir increases levels of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.levalbuterolimipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacinimipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazolelevoketoconazole will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.levorphanollevorphanol and imipramine both increase sedation. Use Caution/Monitor.levothyroxinelevothyroxine increases effects of imipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liothyronineliothyronine increases effects of imipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liotrixliotrix increases effects of imipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.lisdexamfetamineimipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.imipramine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome